ASCEND-D
Anaemia Studies in CKD: Daprodustat — Dialysis
Patient / Population Intervention / Exposure Comparison Outcome
In 2,964 dialysis patients with anaemia, the oral HIF prolyl-hydroxylase inhibitor daprodustat was non-inferior for haemoglobin and cardiovascular safety compared with erythropoiesis-stimulating agents.
N
2,964
Design
Open-label RCT
Endpoint
Change in haemoglobin; major adverse cardiovascular events
Relevance
2
ResultHaemoglobin non-inferior; MACE HR 0.93 (95% CI 0.81–1.07).
Singh AK, et al. N Engl J Med. 2021;385(25):2325-2335. 10.1056/NEJMoa2113379
Discussion & critique
Supported approval of an oral anaemia agent for dialysis patients; non-dialysis use is more cautious.